Related Experiment Video
Updated: Apr 14, 2026
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
8.1K
Targeting PTEN-defined breast cancers with a one-two punch
Leonard B Maggi1, Jason D Weber2
1ICCE Institute and Department of Internal Medicine, Division of Molecular Oncology, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, 63110, USA. lmaggi@dom.wustl.edu.
Breast Cancer Research : BCR
|April 19, 2015
Summary
Researchers identified that low phosphatase and tensin homolog (PTEN) levels drive endocrine resistance in Luminal B breast cancer. Combining endocrine therapy with PI3K pathway inhibitors may overcome this resistance in PTEN-low tumors.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Breast cancer is classified into five subtypes, guiding treatment decisions.
- Targeted therapies show limited success across subtypes.
- Luminal B breast cancer often shows early relapse and poor prognosis, similar to basal-like cancers.
Related Concept Videos
02:57Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
02:57Targeted Cancer Therapies
1.8K
1.8K